Literature DB >> 19724706

Imported malaria in Korea: a 13-year experience in a single center.

Hae Suk Cheong1, Ki-Tae Kwon, Ji-Young Rhee, Seong Yeol Ryu, Dong Sik Jung, Sang Taek Heo, Sang Yop Shin, Doo Ryun Chung, Kyong Ran Peck, Jae-Hoon Song.   

Abstract

The incidence of imported malaria has been increasing in Korea. We reviewed data retrospectively to evaluate the epidemiology, clinical features, and outcomes of imported malaria from 1995 to 2007 in a university hospital. All patients diagnosed with imported malaria were included. Imported malaria was defined as a positive smear for malaria that was acquired in a foreign country. A total of 49 patients (mean age, 35.7 year; M : F = 38 : 11) were enrolled. The predominant malarial species was Plasmodium falciparum (73.5%), and the most frequent area of acquisition was Africa (55.1%), followed by Southeast Asia (22.4%) and South Asia (18.4%). Fourteen-patients (30.6%) suffered from severe malaria caused by P. falciparum and 1 patient (2.0%) died of multiorgan failure. Most of the patients were treated with mefloquine (79.2%) or quinine (10.2%); other antimalarial agents had to be given in 13.2% treated with mefloquine and 44.4% with quinine due to adverse drug events (ADEs). P. falciparum was the most common cause of imported malaria, with the majority of cases acquired from Africa, and a significant number of patients had severe malaria. Alternative antimalarial agents with lower rates of ADEs might be considered for effective treatment instead of mefloquine and quinine.

Entities:  

Keywords:  Plasmodium; adverse drug events; imported malaria; mefloquine; quinine

Mesh:

Substances:

Year:  2009        PMID: 19724706      PMCID: PMC2735698          DOI: 10.3347/kjp.2009.47.3.299

Source DB:  PubMed          Journal:  Korean J Parasitol        ISSN: 0023-4001            Impact factor:   1.341


  5 in total

Review 1.  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  1990       Impact factor: 2.184

2.  Clinical characteristics of imported malaria in Japan: analysis at a referral hospital.

Authors:  Toshiyuki Miura; Mikio Kimura; Tomohiko Koibuchi; Tokiomi Endo; Hitomi Nakamura; Takashi Odawara; Yusuke Wataya; Tetsuya Nakamura; Aikichi Iwamoto
Journal:  Am J Trop Med Hyg       Date:  2005-09       Impact factor: 2.345

3.  Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea.

Authors:  Eun-Taek Han; Duk-Hyoung Lee; Ki-Dong Park; Won-Seok Seok; Young-Soo Kim; Takafumi Tsuboi; Eun-Hee Shin; Jong-Yil Chai
Journal:  Korean J Parasitol       Date:  2006-12       Impact factor: 1.341

Review 4.  Malaria.

Authors:  Brian M Greenwood; Kalifa Bojang; Christopher J M Whitty; Geoffrey A T Targett
Journal:  Lancet       Date:  2005 Apr 23-29       Impact factor: 79.321

5.  Parasitological Studies Of Korean Forces In South Vietnam: I. Examination Of Blood Films On Malaria Patients.

Authors:  Byong Seol Seo; Soon Hyung Lee; Jong June Yoon; Yong Suk Ryang
Journal:  Kisaengchunghak Chapchi       Date:  1970-04
  5 in total
  2 in total

1.  An imported case of severe falciparum malaria with prolonged hemolytic anemia clinically mimicking a coinfection with babesiosis.

Authors:  Young Ju Na; Jong-Yil Chai; Bong-Kwang Jung; Hyun Jung Lee; Ji Young Song; Ji Hye Je; Ji Hye Seo; Sung Hun Park; Ji Seon Choi; Min Ja Kim
Journal:  Korean J Parasitol       Date:  2014-12-23       Impact factor: 1.341

2.  Genetic Diversity and Distribution of Blastocystis Subtype 3 in Human Populations, with Special Reference to a Rural Population in Central Mexico.

Authors:  Liliana Rojas-Velázquez; Patricia Morán; Angélica Serrano-Vázquez; Leonardo D Fernández; Horacio Pérez-Juárez; Augusto C Poot-Hernández; Tobías Portillo; Enrique González; Eric Hernández; Oswaldo Partida-Rodríguez; Miriam E Nieves-Ramírez; Ulises Magaña; Javier Torres; Luis E Eguiarte; Daniel Piñero; Cecilia Ximénez
Journal:  Biomed Res Int       Date:  2018-03-18       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.